Form 4: Stryker Director Giovanni Caforio Receives RSU Grant

Stryker Corporation Director Giovanni Caforio was granted 762 restricted stock units as part of his compensation package.

Summary

• Director Giovanni Caforio acquired 762 restricted stock units (RSUs) on May 6, 2026.
• Each RSU represents a contingent right to receive one share of Stryker common stock.
• The RSUs are scheduled to vest on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027.
• Following this transaction, the director's total beneficial ownership of Stryker common stock is 4,530 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no material impact on company operations.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the equity grant is subject to market fluctuations in Stryker Corporation's share price.

Future Outlook

The RSUs will vest in May 2027, contingent upon the director's continued service or the timing of the 2027 Annual Meeting.

Management Comments

• The filing includes a standard Power of Attorney authorizing designated individuals to handle SEC filings on behalf of the director.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the medical technology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with compensation practices at peer medical device companies like Medtronic and Boston Scientific.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 762 RSUs on or before May 6, 2027.

Key Dates

Keywords

Stryker, SYK, Director, Insider Transaction, Restricted Stock Units, Equity Compensation